GlassScriptPhysician profile
Caitlin M G Mcnulty
NPI 1467895680
$966.06
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $136 · 2021: $203 · 2022: $271 · 2023: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $112.72 | 2019-2022 | |
| Octapharma USA, INC. | $107.72 | 2019-2021 | |
| Pfizer INC. | $76.04 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $65.02 | 2021-2022 | |
| Philips North America LLC | $57.52 | 2019-2020 | |
| Genzyme Corporation | $56.66 | 2020-2023 | |
| Amgen INC. | $54.72 | 2021-2023 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $52.10 | 2021-2023 | Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $48.02 | 2020-2022 | |
| Genentech USA, INC. | $39.71 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $39.46 | 2022-2023 | Orladeyo |
| Pharming Healthcare, INC. | $35.40 | 2019-2022 | |
| Kaleo, INC. | $35.35 | 2022 | |
| Glaxosmithkline, LLC. | $33.32 | 2020-2022 | |
| Phadia US INC. | $30.74 | 2021-2023 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.57 | 2022-2023 | Spiriva Respimat |
| Merck Sharp & Dohme LLC | $19.09 | 2023 | |
| Advanced Respiratory, INC | $17.97 | 2019 | |
| Horizon Therapeutics Plc | $16.84 | 2023 | Actimmune |
| Leo Pharma INC. | $13.85 | 2023 | Adbry |
| Aimmune Therapeutics, INC. | $12.97 | 2020 | |
| Incyte Corporation | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Mcnulty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.